Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor. - Wikidata - awgldk - TriplyDB

Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor.

Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor.

http://www.wikidata.org/entity/Q34958178

about

Macrocyclic histone deacetylase inhibitors Tiny Microbes with a Big Impact: The Role of Cyanobacteria and Their Metabolites in Shaping Our Future Largazole and its derivatives selectively inhibit ubiquitin activating enzyme (e1)Chemical phylogenetics of histone deacetylases.Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides.Biological evaluation of new largazole analogues: alteration of macrocyclic scaffold with click chemistry.Potent and orally efficacious bisthiazole-based histone deacetylase inhibitors Enzymatic activation of a matrix metalloproteinase inhibitor Synthesis and conformation-activity relationships of the peptide isosteres of FK228 and largazole.Investigation of self-immolative linkers in the design of hydrogen peroxide activated metalloprotein inhibitors.A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold Evaluation of class I HDAC isoform selectivity of largazole analogues Modulation of Activity Profiles for Largazole-Based HDAC Inhibitors through Alteration of Prodrug Properties Synthesis and biological evaluation of largazole analogues with modified surface recognition cap groups Total synthesis of Lys(3) tamandarin M: a potential affinity ligand.In Vitro and In Vivo Osteogenic Activity of Largazole.Macrolactonization of peptide thioesters catalyzed by imidazole and its application in the synthesis of kahalalide B and analogues Biological targets and mechanisms of action of natural products from marine cyanobacteria.Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere Natural products synthesis: enabling tools to penetrate Nature's secrets of biogenesis and biomechanism.Variable active site loop conformations accommodate the binding of macrocyclic largazole analogues to HDAC8 Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes.Modular synthesis and biological activity of pyridyl-based analogs of the potent Class I Histone Deacetylase Inhibitor Largazole.Largazole: from discovery to broad-spectrum therapy.Largazole, a class I histone deacetylase inhibitor, enhances TNF-α-induced ICAM-1 and VCAM-1 expression in rheumatoid arthritis synovial fibroblasts.Synthesis and histone deacetylase inhibitory activity of largazole analogs: alteration of the zinc-binding domain and macrocyclic scaffold Chasing the treasures of the sea - bacterial marine natural products.Discovery and mechanism of natural products as modulators of histone acetylation.Design, synthesis, biological evaluation, and structural characterization of potent histone deacetylase inhibitors based on cyclic alpha/beta-tetrapeptide architectures.Synthesis and HDAC inhibitory activity of isosteric thiazoline-oxazole largazole analogs.Epigenetics in human melanoma.Largazole pharmacokinetics in rats by LC-MS/MS.Probing the biology of natural products: molecular editing by diverted total synthesis.Thiazole and oxazole alkaloids: isolation and synthesis.A review of pharmacological and toxicological potentials of marine cyanobacterial metabolites.Synthesis and biological evaluation of largazole zinc-binding group analogs.Largazole and analogues with modified metal-binding motifs targeting histone deacetylases: synthesis and biological evaluation.Natural and Synthetic Macrocyclic Inhibitors of the Histone Deacetylase Enzymes.A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-β and vascular endothelial growth factor signalling.Total syntheses of the histone deacetylase inhibitors largazole and 2-epi-largazole: application of N-heterocyclic carbene mediated acylations in complex molecule synthesis.

P2860

Q24629065-59705EF3-6823-4C7D-B322-4AB1462D2B78 Q26747668-6ACDEB94-4C53-40F4-82BD-16C746210B94 Q28258201-1F894E29-E739-4C5B-A5F4-744F6C4CF824 Q30977637-7453AF92-A38F-4240-A942-F0C13E57EB0F Q33496543-860310D5-86A6-4514-AE63-A718E008EBEA Q33636013-AE774480-4180-4570-A42C-CA45871AF853 Q33768549-955997D6-955C-41A3-BD9F-F34E606C8CB9 Q33839227-3884CD23-3C7A-4768-BDF1-1BFDE879A0C6 Q33893992-9D53AA17-C530-4504-9418-78464DE6ABB6 Q33934129-C5C3BC14-98B3-4F64-BC06-73E0BD1CBCD0 Q33940304-4CA0AB0A-86C9-4985-8276-C2D6BE48C7A4 Q34054267-AC5FE43E-FA56-4A4E-AEA3-F63B350C40FD Q34063722-1C9BA2AE-B8F9-4F14-9E74-C53CCFF16BEA Q34302247-C9D132B7-507F-4D58-89AD-0B1EAC50AE9B Q34680440-B57B112A-C127-4FD5-829C-67743BC7B18E Q35030533-DB418B05-C57B-4E27-A719-E8961383CD26 Q35055393-2AF1BCBF-890A-4922-AC65-5B2C4C1A7D6A Q35130835-A9C8E07D-69F3-45E3-A271-449F72AE31AF Q35202369-4C7594A1-19AA-4747-ADC0-B872380D0E6C Q35215703-FD8D0066-B0B6-499B-8C10-8E63F8D97361 Q35243482-9C201958-6229-48CF-8054-C9D70C095F35 Q35597103-D5239863-D755-4451-8332-E065EF9F9147 Q35656966-0A92682F-8B54-4866-8C2D-237E29F135D3 Q36649018-59C367C8-AB99-467F-B3A1-7B1896CDBBEE Q37155203-AD709786-92ED-4A8A-8A20-AC35F9CF44D9 Q37170927-86EF8669-E905-453A-939E-793DE5C2A3E5 Q37226088-7B1CE533-65B4-4517-BBEC-C0A61FD5ABBC Q37242496-52287C9E-79ED-4C5B-A7E9-FB2A3CF3290C Q37362478-818D2102-33BF-4E5B-9D52-8DAC6F48B4C8 Q37383739-C609A06D-796C-43FD-85E9-B2F181688DEC Q37531849-17AF6004-64B6-4D1F-8CA2-45AFE0BAC135 Q37667033-95462B22-57C0-4E6C-A69C-C868B4CD1403 Q37809500-E5925860-D407-4855-963B-80CFD5D28D8B Q37817756-BD5C774C-E2A7-48B7-AA84-B50D8F53B123 Q37930568-AC97178D-F2D2-4276-A0E0-680C6C41EACB Q38707248-9A392348-7800-43F8-BD15-B9E1A946644D Q38939048-0F73DC40-71A5-4452-BB01-31AD4C66FF21 Q38982458-E473C3BB-2719-4B40-AEEB-8E77F7725A49 Q39218226-BE444A87-4047-4E48-AFBA-762C8E857F41 Q39606523-F233B324-13B6-4E47-A5D7-519B0C764F03

P2860

Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor.

http://www.wikidata.org/entity/Q34958178

description

2008 nî lūn-bûn

@nan

2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Total synthesis and biological ...... histone deacetylase inhibitor.

@ast

Total synthesis and biological ...... histone deacetylase inhibitor.

@en

Total synthesis and biological ...... histone deacetylase inhibitor.

@nl

type

label

Total synthesis and biological ...... histone deacetylase inhibitor.

@ast

Total synthesis and biological ...... histone deacetylase inhibitor.

@en

Total synthesis and biological ...... histone deacetylase inhibitor.

@nl

prefLabel

Total synthesis and biological ...... histone deacetylase inhibitor.

@ast

Total synthesis and biological ...... histone deacetylase inhibitor.

@en

Total synthesis and biological ...... histone deacetylase inhibitor.

@nl

P1433

Q34958178-8297DEEA-401A-452E-87E7-B23D79B86A92

P1476

Q34958178-826CD287-DB9F-4FC1-8DE6-FFE481AD019C

P2093

Q34958178-392B9488-4517-4F01-8A2B-F6ADA63EA718

Q34958178-3C028324-3A4F-487B-B397-26A45D5A20EC

Q34958178-69741326-4314-48A5-BF7A-CA9791722FAA

Q34958178-785294A5-73CE-4679-97AD-7D24F6CCE6A5

Q34958178-A622EE90-306D-4C97-B56F-2687592EC80C

Q34958178-C98EBCFF-2ABF-45BD-82A3-E835414147B7

P2860

Q34958178-01DF2D54-4162-41D5-9CA6-165E1BFE4ED5

Q34958178-0C1E1067-8AFD-44E4-8206-8242D3CF0F5B

Q34958178-1AF04B16-7D52-464F-831D-B10FDB83A321

Q34958178-2D82BBE8-02FE-4EDF-A95C-415BA897A0B8

Q34958178-77E04086-A463-474F-9C1F-5FF400301DD1

Q34958178-7A43FFDE-C647-4C5D-8150-FEE39AC90EFC

Q34958178-896BA453-258B-4B06-A1D4-D0604B6F3B82

Q34958178-9B83DAB4-8229-4DAA-ACA8-0B8CCE9B7778

Q34958178-A9344584-BA51-4E60-A8BE-507D1C50CB20

Q34958178-AB12C7AC-E31E-4F06-9AEB-1A184B46BAAF

P304

Q34958178-28B67003-534A-42E6-9830-545E71EE88C8

P31

Q34958178-1E87E0D8-84D1-444A-B9DF-91C1FC340879

P356

Q34958178-A4B5B2D4-0B32-4BF1-B8D2-1890116A05C7

P407

Q34958178-0E4F87B6-5E70-4A6D-ACE2-63DE5C48B1E5

P433

Q34958178-D28C2F3A-C3AB-4208-A6F3-3A3E842E6ED3

P478

Q34958178-E3ACB651-625D-43F7-B5F5-712CE1CA0549

P577

Q34958178-D93C0195-EE01-4C69-B988-0FE11B1B61E6

P5875

Q34958178-8545B151-4CC2-46D5-B7AB-F128812B5B2F

P698

Q34958178-ADFA8DBA-024B-4854-BF21-3AB4C0E1A723

P932

Q34958178-E8F694B3-7F7E-4EED-9CBB-5E8FD22BD1EA

P356

P1433

Journal of the American Chemical Society

P1476

Total synthesis and biological ...... histone deacetylase inhibitor.

@en

P2093

Albert Bowers

http://www.w3.org/2001/XMLSchema#string

Jack Taunton

http://www.w3.org/2001/XMLSchema#string

James E Bradner

http://www.w3.org/2001/XMLSchema#string

Nathan West

http://www.w3.org/2001/XMLSchema#string

Robert M Williams

http://www.w3.org/2001/XMLSchema#string

Stuart L Schreiber

http://www.w3.org/2001/XMLSchema#string

P2860

Three proteins define a class of human histone deacetylases related to yeast Hda1p

Improved total synthesis of the potent HDAC inhibitor FK228 (FR-901228)

The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor

A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

Anticancer activities of histone deacetylase inhibitors

Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A

FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity.

FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. II. Structure determination.

FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice.

P304

11219-11222

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JA8033763

http://www.w3.org/2001/XMLSchema#string

P407

P433

33

http://www.w3.org/2001/XMLSchema#string

P478

130

http://www.w3.org/2001/XMLSchema#string

P577

2008-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51416851

http://www.w3.org/2001/XMLSchema#string

P698

18642817

http://www.w3.org/2001/XMLSchema#string

P932

3090445

http://www.w3.org/2001/XMLSchema#string